Innovating Works

TB-QUEST

Financiado
Questioning the Epidemiology of Subclinical Tuberculosis
Tuberculosis (TB) remains a major cause of morbidity and mortality around the world. The majority of TB control policies rely on the binary paradigm of TB, which focus on interventions tackling ‘latent’ TB infection and ‘active’ T... Tuberculosis (TB) remains a major cause of morbidity and mortality around the world. The majority of TB control policies rely on the binary paradigm of TB, which focus on interventions tackling ‘latent’ TB infection and ‘active’ TB disease stages. However, recent evidence disputes this longstanding conceptualization of TB natural history, demonstrating that TB exists on a continuous spectrum of bacterial and immunological responses. Several active case-finding studies have shown that around 50% of the cases in whom Mycobacterium tuberculosis was isolated in sputum were asymptomatic. Subclinical (asymptomatic) TB has lately attracted increased scientific interest since it could play an important role in TB transmission, despite the absence of cough. However, beyond limited evidence on TB transmission based on modelling studies using retrospective data collection, there is not a single field study showing a direct transmission from an index subclinical TB case to a secondary laboratory-confirmed case. If subclinical TB does spread the disease, the consequences for global TB control and research are of paramount importance. I propose to characterize the subclinical TB stage within the natural history of TB and to understand its role in spreading the disease. I have designed a field epidemiological study (TB-QUEST) with the potential to show evidence of effective transmission from subclinical TB cases to close contacts, using pathogen genome sequencing. Additionally, by using innovative wearable technology, I will assess whether objective tools to measure classical TB symptoms match the self-reported absence of symptoms. Thus, I might challenge the current definition of subclinical TB and the usefulness of current TB screening algorithms. Lastly, I will study the clinical trajectory of subclinical TB in order to improve our understanding of its natural history, duration of infectiousness, and factors associated with self-clearance or progression to symptomatic disease. ver más
30/04/2029
FUNDACION PRIVADA...
2M€
Duración del proyecto: 60 meses Fecha Inicio: 2024-04-18
Fecha Fin: 2029-04-30

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-04-18
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2023-STG: ERC STARTING GRANTS
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 2M€
Líder del proyecto
FUNDACION PRIVADA INSTITUTO DE SALUD GLOBAL B... No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5 27M